154 related articles for article (PubMed ID: 10052896)
1. Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid and ethambutol.
Abate G; Miörner H
J Antimicrob Chemother; 1998 Dec; 42(6):735-40. PubMed ID: 10052896
[TBL] [Abstract][Full Text] [Related]
2. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination.
Pagliotto AD; Caleffi-Ferracioli KR; Lopes MA; Baldin VP; Leite CQ; Pavan FR; Scodro RB; Siqueira VL; Cardoso RF
J Microbiol Immunol Infect; 2016 Dec; 49(6):980-983. PubMed ID: 26454420
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Zhang D; Wang Y; Lu J; Pang Y
Antimicrob Agents Chemother; 2016 Jan; 60(1):393-9. PubMed ID: 26525785
[TBL] [Abstract][Full Text] [Related]
4. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
Gonzalo X; Drobniewski F
J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
[TBL] [Abstract][Full Text] [Related]
5. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
[TBL] [Abstract][Full Text] [Related]
6. In-vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium kansasii to amoxycillin and ticarcillin in combination with clavulanic acid.
Wong CS; Palmer GS; Cynamon MH
J Antimicrob Chemother; 1988 Dec; 22(6):863-6. PubMed ID: 3149633
[TBL] [Abstract][Full Text] [Related]
7. Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.
Segura C; Salvadó M; Collado I; Chaves J; Coira A
Antimicrob Agents Chemother; 1998 Jun; 42(6):1524-6. PubMed ID: 9624510
[TBL] [Abstract][Full Text] [Related]
8. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
Dinçer I; Ergin A; Kocagöz T
Int J Antimicrob Agents; 2004 Apr; 23(4):408-11. PubMed ID: 15081094
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.
Cohen KA; El-Hay T; Wyres KL; Weissbrod O; Munsamy V; Yanover C; Aharonov R; Shaham O; Conway TC; Goldschmidt Y; Bishai WR; Pym AS
EBioMedicine; 2016 Jul; 9():170-179. PubMed ID: 27333036
[TBL] [Abstract][Full Text] [Related]
10. Molecular Screening Versus Phenotypic Susceptibility Testing of Multidrug-Resistant Mycobacterium tuberculosis Isolates for Streptomycin and Ethambutol.
Al-Mutairi NM; Ahmad S; Mokaddas E
Microb Drug Resist; 2018 Sep; 24(7):923-931. PubMed ID: 29336677
[TBL] [Abstract][Full Text] [Related]
11. Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Antimicrob Agents Chemother; 2015; 59(6):3630-2. PubMed ID: 25824227
[TBL] [Abstract][Full Text] [Related]
12. Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae.
Cooper CE; Slocombe B; White AR
J Antimicrob Chemother; 1990 Sep; 26(3):371-80. PubMed ID: 2121699
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antimycobacterial activity between ethambutol and the beta-lactam drug cefepime.
Abate G; Hoffner SE
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):119-22. PubMed ID: 9294701
[TBL] [Abstract][Full Text] [Related]
14. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
Jacobs MR; Spangler SK; Appelbaum PC
J Antimicrob Chemother; 1990 Sep; 26(3):361-70. PubMed ID: 2228827
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.
Cynamon MH; Palmer GS
Antimicrob Agents Chemother; 1983 Sep; 24(3):429-31. PubMed ID: 6416162
[TBL] [Abstract][Full Text] [Related]
16. Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations.
Kurz SG; Wolff KA; Hazra S; Bethel CR; Hujer AM; Smith KM; Xu Y; Tremblay LW; Blanchard JS; Nguyen L; Bonomo RA
Antimicrob Agents Chemother; 2013 Dec; 57(12):6085-96. PubMed ID: 24060876
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
Livermore DM; Seetulsingh P
J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic interaction of amoxycillin and clavulanic acid against 132 beta-lactamase positive Haemophilus isolates: a comparison with some other oral agents.
Lapointe JR; Lavallée C
J Antimicrob Chemother; 1987 Jan; 19(1):49-58. PubMed ID: 3494009
[TBL] [Abstract][Full Text] [Related]
19. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates.
Rey-Jurado E; Tudó G; de la Bellacasa JP; Espasa M; González-Martín J
Int J Antimicrob Agents; 2013 Mar; 41(3):278-80. PubMed ID: 23312604
[TBL] [Abstract][Full Text] [Related]
20. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
Cavanaugh JS; Jou R; Wu MH; Dalton T; Kurbatova E; Ershova J; Cegielski JP;
J Antimicrob Chemother; 2017 Jun; 72(6):1678-1687. PubMed ID: 28333192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
